Tocilizumab in refractory Caucasian Takayasu's arteritis: a multicenter study of 54 patients and literature review

被引：18

作者：

Prieto-Pena, Diana ^{[4
]}

Bernabeu, Pilar ^{[5
]}

Vela, Paloma ^{[5
]}

Narvaez, Javier ^{[6
]}

Fernandez-Lopez, Jesus C. ^{[7
]}

Freire-Gonzalez, Mercedes ^{[7
]}

Gonzalez-Alvarez, Beatriz ^{[8
]}

Solans-Laque, Roser ^{[9
]}

Callejas Rubio, Jose L. ^{[10
]}

Ortego, Norberto ^{[10
]}

Fernandez-Diaz, Carlos ^{[11
]}

Rubio, Esteban ^{[12
]}

Garcia-Morillo, Salvador ^{[12
]}

Minguez, Mauricio ^{[13
]}

Fernandez-Carballido, Cristina ^{[13
]}

de Miguel, Eugenio ^{[14
]}

Melchor, Sheila ^{[15
]}

Salgado, Eva ^{[16
]}

Bravo, Beatriz ^{[17
]}

Romero-Yuste, Susana ^{[18
]}

Salvatierra, Juan ^{[10
]}

Hidalgo, Cristina ^{[19
]}

Manrique, Sara ^{[20
]}

Romero-Gomez, Carlos ^{[20
]}

Moya, Patricia ^{[21
]}

Alvarez-Rivas, Noelia ^{[22
]}

Mendizabal, Javier ^{[23
]}

Ortiz-Sanjuan, Francisco ^{[24
]}

Perez de Pedro, Ivan ^{[25
]}

Alonso-Valdivielso, Jose L. ^{[26
]}

Perez-Sanchez, Laura ^{[27
]}

Roldan, Rosa ^{[27
]}

Fernandez-Llanio, Nagore ^{[28
]}

Gomez de la Torre, Ricardo ^{[29
]}

Suarez, Silvia ^{[29
]}

Montesa Cabrera, Maria Jesus ^{[8
]}

Delgado Sanchez, Monica ^{[8
]}

Loricera, Javier ^{[4
]}

Atienza-Mateo, Belen ^{[4
]}

Castaneda, Santos ^{[11
,30
]}

Gonzalez-Gay, Miguel A. ^{[1
,2
,3
]}

Blanco, Ricardo ^{[4
]}

机构：

[1] Hosp Univ Marques de Valdecilla, Rheumatol Div, Res Grp Genet Epidemiol & Atherosclerosis Syst Di, IDIVAL, Ave Valdecilla S-N, Santander 39008, Spain

[2] Univ Cantabria, Sch Med, Santander, Spain

[3] Univ Witwatersrand, Fac Hlth Sci, Sch Physiol, Cardiovasc Pathophysiol & Genom Res Unit, Johannesburg, South Africa

[4] Hosp Univ Marques de Valdecilla, Dept Rheumatol, IDIVAL, Res Grp Genet Epidemiol & Atherosclerosis Syst Di, Santander, Spain

[5] Hosp Gen Alicante, Dept Rheumatol, Alicante, Spain

[6] Hosp Bellvitge Princeps Espanya, Dept Rheumatol, Barcelona, Spain

[7] Complejo Hosp Univ A Coruna, Dept Rheumatol, La Coruna, Spain

[8] Hosp Nuestra Senora Candelaria, Dept Rheumatol, Tenerife, Spain

[9] Hosp Valle De Hebron, Dept Internal Med, Barcelona, Spain

[10] Hosp San Cecilio, Autoimmune Dis Unit, Granada, Spain

[11] Hosp Univ Princesa, Dept Rheumatol, IIS Princesa, Madrid, Spain

[12] Hosp Virgen Rocio, Autoimmune Dis Unit, Seville, Spain

[13] Hosp San Juan Alicante, Dept Rheumatol, Alicante, Spain

[14] Hosp Univ La Paz, Dept Rheumatol, Madrid, Spain

[15] Hosp Univ 12 Octubre, Dept Rheumatol, Madrid, Spain

[16] Complejo Hosp Univ Ourense, Dept Rheumatol, Orense, Spain

[17] Hosp Virgen Nieves, Dept Rheumatol, Granada, Spain

[18] Complejo Hosp Univ Pontevedra, Dept Rheumatol, Pontevedra, Spain

[19] Complejo Univ Salamanca, Dept Rheumatol, Salamanca, Spain

[20] Hosp Reg Malaga, Autoimmune Dis Unit, Malaga, Spain

[21] Hosp Santa Creu & Sant Pau, Dept Rheumatol, Barcelona, Spain

[22] Hosp Univ San Agustin, Dept Rheumatol, Aviles, Spain

[23] Complejo Hosp Navarra, Dept Rheumatol, Pamplona, Spain

[24] Hosp Univ & Politecn La Fe, Dept Rheumatol, Valencia, Spain

[25] Hosp Carlos Haya, Autoimmune Dis Unit, Malaga, Spain

[26] Hosp Univ Burgos, Dept Rheumatol, Burgos, Spain

[27] Hosp Univ Reina Sofia, Dept Rheumatol, Cordoba, Spain

[28] Hosp Arnau Vilanova, Dept Rheumatol, Valencia, Spain

[29] Hosp Univ Cent Asturias, Autoimmune Dis Unit, Oviedo, Spain

[30] Univ Autonoma Madrid IUAMI, UAM ROCHE, EPID Future, Madrid, Spain

来源：

THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE | 2021年 / 13卷

关键词：

biological therapy; Caucasian; cDMARDs; Takayasu's arteritis; Tocilizumab; DISEASE-ACTIVITY; EPIDEMIOLOGY; EFFICACY; FEATURES; CRITERIA; OUTCOMES; SAFETY; JAPAN;

D O I：

10.1177/1759720X211020917

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective: To assess the efficacy and safety of tocilizumab (TCZ) in Caucasian patients with refractory Takayasu's arteritis (TAK) in clinical practice. Methods: A multicenter study of Caucasian patients with refractory TAK who received TCZ. The outcome variables were remission, glucocorticoid-sparing effect, improvement in imaging techniques, and adverse events. A comparative study between patients who received TCZ as monotherapy (TCZ(MONO)) and combined with conventional disease modifying anti-rheumatic drugs (cDMARDs) (TCZ(COMBO)) was performed. Results: The study comprised 54 patients (46 women/8 men) with a median [interquartile range (IQR)] age of 42.0 (32.5-50.5) years. TCZ was started after a median (IQR) of 12.0 (3.0-31.5) months since TAK diagnosis. Remission was achieved in 12/54 (22.2%), 19/49 (38.8%), 23/44 (52.3%), and 27/36 (75%) patients at 1, 3, 6, and 12 months, respectively. The prednisone dose was reduced from 30.0 mg/day (12.5-50.0) to 5.0 (0.0-5.6) mg/day at 12 months. An improvement in imaging findings was reported in 28 (73.7%) patients after a median (IQR) of 9.0 (6.0-14.0) months. Twenty-three (42.6%) patients were on TCZ(MONO) and 31 (57.4%) on TCZ(COMBO): MTX (n = 28), cyclosporine A (n = 2), azathioprine (n = 1). Patients on TCZ(COMBO) were younger [38.0 (27.0-46.0) versus 45.0 (38.0-57.0)] years; difference (diff) [95% confidence interval (CI) = -7.0 (-17.9, -0.56] with a trend to longer TAK duration [21.0 (6.0-38.0) versus 6.0 (1.0-23.0)] months; diff 95% CI = 15 (-8.9, 35.5), and higher c-reactive protein [2.4 (0.7-5.6) versus 1.3 (0.3-3.3)] mg/dl; diff 95% CI = 1.1 (-0.26, 2.99). Despite these differences, similar outcomes were observed in both groups (log rank p = 0.862). Relevant adverse events were reported in six (11.1%) patients, but only three developed severe events that required TCZ withdrawal. Conclusion: TCZ in monotherapy, or combined with cDMARDs, is effective and safe in patients with refractory TAK of Caucasian origin.

引用

页数：12

共 50 条

[1] Tocilizumab in Caucasian Patients with Takayasu Arteritis: Multicenter Study of 54 Patients
Prieto-Pena, Diana
Bernabeu, Pilar
Vela, Paloma
Narvaez, Javier
Carlos Fernandez-Lopez, Jesus
Freire, Mercedes
Gonzalez-Alvarez, Beatriz
Solans-Laque, Roser
Luis Callejas, Jose
Ortego, Norberto
Fernandez-Diaz, Carlos
Rubio Romero, Esteban
Garcia-Morillo, Salvador
Minguez, Mauricio
Carballido, Cristina
De Miguel, Eugenio
Melchor, Sheila
Salgado, Eva
Bravo, Beatriz
Romero-Yuste, Susana
Salvatierra, Juan
Hidalgo, Cristina
Manrique Arija, Sara
Romero Gomez, Carlos
Moya, Patricia
Alvarez-Rivas, Noelia
Mendizabal-Mateos, Javier
Ortiz-Sanjuan, Francisco
Perez De Pedro, Ivan
Alonso-Valdivielso, Jose L.
Perez-Sanchez, Laura
Roldan, Rosa
Fernandez-Llanio, Nagore
Gomez de la Torre, Ricardo
Suarez, Silvia
Montesa Cabrera, Mara Jess
Delgado Sanchez, Monica
Loricera, Javier
Atienza-Mateo, Belen
Angel Gonzalez-Gay, Miguel
Blanco, Ricardo
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3925 - 3927
[2] TOCILIZUMAB FOR TAKAYASU ARTERITIS: MULTICENTER STUDY OF 54 WHITE PATIENTS
Prieto-Pena, D.
Bernabeu, P.
Vela-Casasempere, P.
Narvaez, J.
Fernandez-Lopez, C.
Freire Gonzalez, M.
Gonzalez-Alvarez, B.
Solans-Laque, R.
Callejas-Rubio, J. L.
Ortego, N.
Fernandez-Diaz, C.
Rubio Romero, E.
Garcia Morillo, S.
Minguez, M.
Fernandez-Carballido, C.
De Miguel, E.
Melchor, S.
Salgado-Perez, E.
Bravo, B.
Romero-Yuste, S.
Salvatierra, J.
Hidalgo, C.
Manrique Arija, S.
Romero-Gomez, C.
Moya, P.
Alvarez-Rivas, N.
Mendizabal, J.
Ortiz Sanjuan, F. M.
Perez de Pedro, I.
Alonso Valdivieso, J. L.
Laura, P. S.
Rosa, R. M.
Fernandez-Llanio, N.
Gomez de la Torre, R.
Suarez, S.
Montesa, M. J.
Delgado Sanchez, M.
Loricera, J.
Atienza-Mateo, B.
Castaneda, S.
Gonzalez-Gay, M. A.
Blanco, R.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1208 - 1209
[3] Tocilizumab in Refractory Takayasu Arteritis. a Multicenter Study
Palmou, Natalia
Santos-Gomez, Montserrat
Loricera, Javier
Blanco, Ricardo
Hernandez, Jose L.
Castaneda, Santos
Humbria, Alicia
Ortego-Centeno, Norberto
Bravo, Beatriz
Freire, Mercedes
Melchor, Sheila
Minguez, Mauricio
Salvatierra, Juan
Gonzalez-Vela, Carmen
Calvo-Rio, Vanesa
Pina, Trinitario
Angel Gonzalez-Gay, Miguel
ARTHRITIS & RHEUMATOLOGY, 2015, 67
[4] Efficacy of tocilizumab for refractory Takayasu arteritis: a retrospective study and literature review
Haiyan Li
Zongwen Shuai
Heart and Vessels, 2022, 37 : 884 - 894
[5] Efficacy of tocilizumab for refractory Takayasu arteritis: a retrospective study and literature review
Li, Haiyan
Shuai, Zongwen
HEART AND VESSELS, 2022, 37 (05) : 884 - 894
[6] Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review
Loricera, J.
Blanco, R.
Hernandez, J. L.
Castaneda, S.
Humbria, A.
Ortego, N.
Bravo, B.
Freire, M.
Melchor, S.
Minguez, M.
Salvatierra, J.
Gonzalez-Vela, C.
Calvo-Rio, V.
Santos-Gomez, M.
Pina, T.
Gonzalez-Gay, M. A.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (03) : S44 - S53
[7] Tocilizumab in refractory Takayasu arteritis: Case series and literature review
Abisror, N.
Mekinian, A.
Lavigne, C.
Vandenehende, M. -A.
Soussan, M.
Fain, O.
PRESSE MEDICALE, 2013, 42 (04): : 725 - 726
[8] Tocilizumab In Refractory Takayasu Arteritis: a Case Series and Updated Literature Review
Abisror, Noemie
Mekinian, Arsene
Lavigne, Christian
Vandenhende, Marie Anne
Soussan, Michael
Fain, Olivier
ARTHRITIS AND RHEUMATISM, 2013, 65 : S713 - S714
[9] Tocilizumab in refractory Takayasu arteritis: A case series and updated literature review
Abisror, Noemie
Mekinian, Arsene
Lavigne, Christian
Vandenhende, Marie-Anne
Soussan, Michael
Fain, Olivier
AUTOIMMUNITY REVIEWS, 2013, 12 (12) : 1143 - 1149
[10] Tocilizumab for the Treatment of Patients With Refractory Takayasu Arteritis
Nakaoka, Yoshikazu
Higuchi, Kaori
Arita, Yoh
Otsuki, Michio
Yamamoto, Kaori
Hashimoto-Kataka, Takahiro
Yasui, Taku
Ikeoka, Kuniyasu
Ohtani, Tomohito
Sakata, Yasushi
Shima, Yoshihito
Kumanogoh, Atsushi
Yamauchi-Takihara, Keiko
Tanaka, Toshio
Kishimoto, Tadamitsu
Komuro, Issei
INTERNATIONAL HEART JOURNAL, 2013, 54 (06) : 405 - 411

← 1 2 3 4 5 →